12/16/2023 0 Comments Nasdaq alt![]() ![]() About AltimmuneĪltimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Hedge funds and other institutional investors own 81.03% of the company's stock. Finally, King Wealth acquired a new position in shares of Altimmune in the 2nd quarter valued at $117,000. Point72 Hong Kong Ltd acquired a new position in shares of Altimmune in the 4th quarter valued at $49,000. Emfo LLC acquired a new position in shares of Altimmune in the 2nd quarter valued at $44,000. Amalgamated Bank acquired a new position in shares of Altimmune in the 1st quarter valued at $29,000. FNY Investment Advisers LLC purchased a new position in Altimmune in the second quarter worth approximately $31,000. Several hedge funds and other institutional investors have recently made changes to their positions in the business. Insiders own 3.19% of the company's stock. Over the last ninety days, insiders sold 112,588 shares of company stock worth $1,392,554. The disclosure for this sale can be found here. Following the sale, the insider now owns 17,700 shares of the company's stock, valued at $212,400. The shares were sold at an average price of $12.00, for a total transaction of $448,224.00. Also, insider M Scot Roberts sold 37,352 shares of Altimmune stock in a transaction dated Monday, June 27th. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The shares were sold at an average price of $11.75, for a total transaction of $206,917.50. In other Altimmune news, Director Diane Jorkasky sold 17,610 shares of Altimmune stock in a transaction dated Monday, June 27th. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Following the completion of the sale, the insider now directly owns 17,700 shares in the company, valued at $212,400. In other Altimmune news, insider M Scot Roberts sold 37,352 shares of Altimmune stock in a transaction dated Monday, June 27th. ![]() ![]() On average, equities analysts expect that Altimmune will post -1.86 EPS for the current year. During the same period in the prior year, the firm posted ($0.40) earnings per share. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.74 million. Altimmune had a negative net margin of 2,788.75% and a negative return on equity of 47.54%. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.03. Altimmune (NASDAQ:ALT – Get Rating) last announced its quarterly earnings results on Thursday, August 11th. The company has a market capitalization of $606.50 million, a PE ratio of -5.52 and a beta of 0.19. Altimmune has a 1 year low of $3.83 and a 1 year high of $23.49. The company's fifty day moving average price is $15.72 and its 200 day moving average price is $10.00. Shares of NASDAQ ALT opened at $12.37 on Friday. Get Altimmune alerts: Altimmune Stock Performance Finally, Jefferies Financial Group increased their target price on shares of Altimmune from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, August 31st. HC Wainwright increased their target price on shares of Altimmune from $25.00 to $50.00 and gave the company a "buy" rating in a research report on Wednesday, August 17th. Riley increased their price objective on shares of Altimmune from $21.00 to $26.00 and gave the company a "buy" rating in a report on Friday, August 12th. JMP Securities reaffirmed a "buy" rating and set a $22.00 price objective on shares of Altimmune in a report on Wednesday, June 1st. Guggenheim decreased their price objective on shares of Altimmune from $31.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, September 16th. The average 12-month price objective among brokerages that have covered the stock in the last year is $30.67.ĪLT has been the topic of several recent analyst reports. Six investment analysts have rated the stock with a buy recommendation. (NASDAQ:ALT – Get Rating) have received an average recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat reports. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |